r-chop dose intensity and survival outcomes in dlbcl
Published 3 years ago • 1.5K plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
2:33
tailoring chemotherapy: r-chop dose attenuation in elderly dlbcl
-
2:15
frontmind: tafasitamab lenalidomide r-chop vs r-chop for newly diagnosed high-risk dlbcl
-
5:30
how the treatment landscape of dlbcl is changing: r-chop vs pola-r-chp
-
1:12
smart stop: moving away from r-chop in dlbcl
-
1:44
remodl-b: bortezomib r-chop versus r-chop in patients with dlbcl
-
2:13
phase ii trial of split-dose r-chop for older patients with dlbcl
-
4:01
first- and second-line treatment in dlbcl
-
1:40
fracture risk in older dlbcl patients after r-chop
-
1:51
pet2-assoicated outcomes in patients with dlbcl
-
1:00
phase ib trial of r-chop plus iberdomide or cc-99282 in aggressive b-cell lymphoma
-
4:40
reduced r-chop in favourable-prognosis dlbcl doesn't compromise outlook
-
1:46
r-chop versus r-bendamustine in fl
-
2:00
the use of chemotherapy in r/r hodgkin and non-hodgkin lymphomas
-
1:45
ham-ven as salvage treatment for r/r aml: results from the sal-relax trial
-
4:16
rchop chemo
-
0:45
difference between quality of life & patient-reported outcomes
-
0:37
the mechanism of treatment resistance in aml: do cd8-expressing t-cells become exhausted?
-
1:22
safety and efficacy of cc-99282 in the treatment of r/r nhl